stoxline Quote Chart Rank Option Currency Glossary
  
Aclaris Therapeutics, Inc. (ACRS)
2.5  -0.07 (-2.72%)    02-06 11:50
Open: 2.6
High: 2.6
Volume: 216,446
  
Pre. Close: 2.57
Low: 2.445
Market Cap: 268(M)
Technical analysis
2025-02-06 11:16:28 AM
Short term     
Mid term     
Targets 6-month :  3.03 1-year :  3.26
Resists First :  2.59 Second :  2.79
Pivot price 2.49
Supports First :  2.27 Second :  1.89
MAs MA(5) :  2.49 MA(20) :  2.49
MA(100) :  2.33 MA(250) :  1.65
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  67.5 D(3) :  59.2
RSI RSI(14): 45.4
52-week High :  5.17 Low :  0.95
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACRS ] has closed above bottom band by 49.3%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.6 - 2.61 2.61 - 2.62
Low: 2.43 - 2.45 2.45 - 2.46
Close: 2.55 - 2.57 2.57 - 2.59
Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Headline News

Wed, 05 Feb 2025
Aclaris Therapeutics forms new Scientific Advisory Board - MSN

Fri, 31 Jan 2025
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts - MyChesCo

Thu, 30 Jan 2025
Aclaris Therapeutics Appoints Marianne Mann and Zuzana Diamant to Scientific Advisory Board - citybiz

Sat, 25 Jan 2025
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Purchased by Assenagon Asset Management S.A. - MarketBeat

Sat, 18 Jan 2025
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat

Wed, 20 Nov 2024
Aclaris Therapeutics director acquires $1.5 million in stock - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 107 (M)
Shares Float 55 (M)
Held by Insiders 2.5 (%)
Held by Institutions 58.3 (%)
Shares Short 3,390 (K)
Shares Short P.Month 3,160 (K)
Stock Financials
EPS -0.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.82
Profit Margin -136.7 %
Operating Margin -222.6 %
Return on Assets (ttm) -19.4 %
Return on Equity (ttm) -25.9 %
Qtrly Rev. Growth -53.3 %
Gross Profit (p.s.) -0.72
Sales Per Share 0.25
EBITDA (p.s.) -0.59
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -4.79
PEG Ratio 0
Price to Book value 1.36
Price to Sales 9.84
Price to Cash Flow -14.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android